Q-Med's strong growth continues - report Jan-March 2000

Q-MED's STRONG GROWTH CONTINUES * Turnover increased by 67% for comparable units, to SEK 43.3 (26.0*) million * Continued large investments in research and development - operating income before these costs amounted to SEK 16.3 (9.2*) million, an increase of 77% * Income after financial items increased by 79%, to SEK 8.6 (4.8*) million * Successful launch of PERLANE for facial aesthetics REVENUES Q-Med reports continued strong growth during the first quarter of 2000. Sales amounted to SEK 43.3 (26.0*) million, which is an increase of 67%. Translated to a rolling 12-month period, that is from April 1999 to March 2000, turnover amounted to SEK 143.8 (88.3*) million, an increase of 63%. * Exclusive of Venofer, an intravenous iron preparation that Q-Med had a licensing agreement for in the Nordic countries up until December 31, 1999. Aesthetics @ Sales of SEK 42.4 (25.6) million, an increase of 66% RESTYLANE is the product which is the primary motor behind Q-Med's sales growth. Revenues from RESTYLANE amounted to SEK 34.2 million, which is an increase of 34% compared with the corresponding period the previous year. The increase is due both to increased demand in existing markets and to the establishment of the company in new markets. Further distributors have been added since the turn of the year in Uruguay, the United Arab Emirates and Dubai. Q-Med's facial aesthetic products are thereby sold in more than 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/2000/04/14/20000414BIT00350/bit0002.pdf http://www.bit.se/bitonline/2000/04/14/20000414BIT00350/bit0001.doc